Thalidomide and Venous Thrombosis
Authors: B. Escudier, N. Lassau, S. Leborgne, E. Angevin, A. Laplanche
Journal: Annals of Internal Medicine (2002)

Letters7 May 2002Thalidomide and Venous ThrombosisB. Escudier, MD, N. Lassau, MD, S. Leborgne, MD, PhD, E. Angevin, and A. Laplanche, MDB. Escudier, MDInstitut Gustave Roussy94805 Villejuif, FranceSearch for more papers by this author, N. Lassau, MDInstitut Gustave Roussy94805 Villejuif, FranceSearch for more papers by this author, S. Leborgne, MD, PhDInstitut Gustave Roussy94805 Villejuif, FranceSearch for more papers by this author, E. AngevinInstitut Gustave Roussy94805 Villejuif, FranceSearch for more papers by this author, and A. Laplanche, MDInstitut Gustave Roussy94805 Villejuif, FranceSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-9-200205070-00024 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Thalidomide is an antiangiogenic drug used in cancer therapy. On the basis of encouraging preliminary results, we performed a phase II trial of thalidomide (Laphal, Allauch, France) in 40 patients with metastatic renal-cell carcinoma. The starting dosage of thalidomide was 400 mg/d, with titration to 800 mg/d after 6 or 12 weeks if progressive disease occurred and to 1200 mg/d if disease still progressed with 800 mg/d.Nine of the 40 patients developed venous thrombosis 4 to 12 weeks after starting thalidomide treatment. Thromboses occurred in the legs in 5 patients and in the vena cava in 4 patients. Pulmonary ...References1. Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, et al . Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol. 2000;18:371-5. [PMID: 10637252] CrossrefMedlineGoogle Scholar2. Flageul B, Wallach D, Cavelier-Balloy B, Bachelez H, Carsuzaa F, Dubertret L. [Thalidomide and thrombosis]. Ann Dermatol Venereol. 2000;127:171-4. [PMID: 10739975] MedlineGoogle Scholar3. Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, LeBorgne S, et al. Phase II trial of thalidomide in renal cell carcinoma. Ann Oncol. 2002 [In press]. Google Scholar Author, Article, and Disclosure InformationAffiliations: Institut Gustave Roussy94805 Villejuif, France PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited BySkinSkinArterial thrombosis and thalidomideLetter to the EditorNew Therapeutic Approaches to MyelomaTissue Factor, Thrombin, and CancerThalidomide-associated deep vein thrombosis and pulmonary embolismThrombocytopenia Caused by a Protein Pump Inhibitor; Hepatic Failure Associated with the Benzodiazepine Triazolam; Three Cases of Transient Encephalopathy with Paclitaxel; Thalidomide Problems: Hypothyroidism and Venous Thrombosis; Hypertensive Crisis with St. John's Wort 7 May 2002Volume 136, Issue 9Page: 711KeywordsAdverse eventsAnticoagulantsDrug therapyHemostasisLupus erythematosusPhase 2 trialsProgressive diseasesPulmonary embolismRenal cancerThrombosis ePublished: 7 May 2002 Issue Published: 7 May 2002 CopyrightCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...